Notification

No new Notification messages

Pre-Apply for Manba Finance IPO
Don't miss out on the latest IPOs! Use Bajaj Broking's Pre-Apply feature.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
Trade Now, Pay Later with up to 4x Leverage
Never miss a good trading opportunity due to low funds with our MTF feature.
NSE BSE
emcure pharmaceuticals limited stock

Emcure Pharmaceuticals Limited Share Price

1461.55 -65.04 (-4.26%)
Sep 19 2024 03:30 PM Pharmaceuticals NSE: EMCURE

Emcure Pharmaceuticals Limited Share Price Update

As of the latest trading session, Emcure Pharmaceuticals Limited share price is currently at 1461.55, which is down by -65.04 from its previous closing. Today, the stock has fluctuated between 1441.05 and 1539.95. Over the past year, Emcure Pharmaceuticals Limited has achieved a return of 0.00 %. In the last month alone, the return has been 15.21 %. Read More...

Emcure Pharmaceuticals Limited Performance

Day Range

Low1441.05 High1539.95
1461.55

52 Week Range

Low 1225.00 High 1580.00
1461.55

Emcure Pharmaceuticals Limited Share Price

24398

544210

EMCURE

img img img img
No Data Available

Open Price

1531.00

Prev. Close

1526.60

Volume (Shares)

219260.00

Total traded value

3204.59

Upper Circuit

1679.25

Lower Circuit

1373.95

Note: The current prices & values are delayed, Login to your account for live updates.

Emcure Pharmaceuticals Limited Fundamentals


(Standalone)

Market Cap (Cr) 26476.29
PE Ratio (TTM) 179.39
Book Value / Share 139.77
Beta 0.77
ROE 9.01%
EPS (TTM) 8.90
Dividend Yield 0.13%
Net Profit Qtr (Cr) 40.45

Emcure Pharmaceuticals Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars JUN 2024 (Values in Cr)
Revenue 970.29
Operating Expense 947.75
Net Profit 40.45
Net Profit Margin (%) 4.16
Earnings Per Share (EPS) 2.23
EBITDA 147.70
Effective Tax Rate (%) 26.52
Particulars MAR 2024 (Values in Cr)
Revenue 902.55
Operating Expense 891.91
Net Profit 28.98
Net Profit Margin (%) 3.21
Earnings Per Share (EPS) 1.60
EBITDA 131.15
Effective Tax Rate (%) 18.32
Particulars JUN 2023 (Values in Cr)
Revenue 836.96
Operating Expense 810.51
Net Profit 36.22
Net Profit Margin (%) 4.32
Earnings Per Share (EPS) 2.00
EBITDA 132.89
Effective Tax Rate (%) 24.33
Particulars MAR 2024 (Values in Cr)
Revenue 3497.66
Operating Expense 3426.68
Net Profit 160.83
Net Profit Margin (%) 4.59
Earnings Per Share (EPS) 8.89
EBITDA 570.83
Effective Tax Rate (%) 19.54
Particulars MAR 2023 (Values in Cr)
Revenue 3107.09
Operating Expense 3013.95
Net Profit 160.06
Net Profit Margin (%) 5.15
Earnings Per Share (EPS) 9.07
EBITDA 557.69
Effective Tax Rate (%) 24.62
Particulars MAR 2022 (Values in Cr)
Revenue 3387.24
Operating Expense 2903.50
Net Profit 446.81
Net Profit Margin (%) 13.19
Earnings Per Share (EPS) 24.66
EBITDA 927.34
Effective Tax Rate (%) 27.51
Particulars MAR 2021 (Values in Cr)
Revenue 3153.66
Operating Expense 2689.83
Net Profit 420.48
Net Profit Margin (%) 13.33
Earnings Per Share (EPS) 23.25
EBITDA 837.03
Effective Tax Rate (%) 24.57
Particulars MAR 2020 (Values in Cr)
Revenue 2375.71
Operating Expense 2244.48
Net Profit 175.21
Net Profit Margin (%) 7.37
Earnings Per Share (EPS) 9.69
EBITDA 516.87
Effective Tax Rate (%) 22.02
Particulars MAR 2024 (Values in Cr)
Book Value / Share 162.97
ROE % 19.35
ROCE % 18.23
Total Debt to Total Equity 0.86
EBITDA Margin 19.18
Particulars MAR 2023 (Values in Cr)
Book Value / Share 138.30
ROE % 25.03
ROCE % 20.75
Total Debt to Total Equity 1.01
EBITDA Margin 20.40
Particulars MAR 2022 (Values in Cr)
Book Value / Share 109.90
ROE % 32.98
ROCE % 25.00
Total Debt to Total Equity 1.06
EBITDA Margin 23.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 125.68
ROE % 20.14
ROCE % 21.08
Total Debt to Total Equity 1.11
EBITDA Margin 24.83
Particulars MAR 2020 (Values in Cr)
Book Value / Share 105.72
ROE % 9.43
ROCE % 10.41
Total Debt to Total Equity 1.19
EBITDA Margin 15.66
Particulars MAR 2023 (Values in Cr)
Book Value / Share 101.84
ROE % 9.01
ROCE % 10.71
Total Debt to Total Equity 0.91
EBITDA Margin 17.95
Particulars MAR 2022 (Values in Cr)
Book Value / Share 94.69
ROE % 22.26
ROCE % 20.50
Total Debt to Total Equity 0.79
EBITDA Margin 27.38
Particulars MAR 2021 (Values in Cr)
Book Value / Share 127.27
ROE % 19.95
ROCE % 18.77
Total Debt to Total Equity 0.68
EBITDA Margin 26.72
Particulars MAR 2020 (Values in Cr)
Book Value / Share 105.86
ROE % 11.26
ROCE % 13.14
Total Debt to Total Equity 0.67
EBITDA Margin 23.79
Particulars MAR 2019 (Values in Cr)
Book Value / Share 98.29
ROE % 17.79
ROCE % 17.73
Total Debt to Total Equity 0.73
EBITDA Margin 25.53
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 232.40
Total Assets 7806.16
Total Liabilities 7806.16
Total Equity 3121.76
Share Outstanding 181152116
Price to Book Ratio 0.00
Return on Assets (%) 6.38
Return on Capital (%) 9.56
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 458.25
Total Assets 6672.53
Total Liabilities 6672.53
Total Equity 2649.66
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 7.97
Return on Capital (%) 10.98
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 313.29
Total Assets 6063.46
Total Liabilities 6063.46
Total Equity 2114.14
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 10.92
Return on Capital (%) 15.78
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 523.53
Total Assets 6807.39
Total Liabilities 6807.39
Total Equity 2368.01
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 6.14
Return on Capital (%) 9.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 163.83
Total Assets 6004.05
Total Liabilities 6004.05
Total Equity 1984.36
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 1.39
Return on Capital (%) 2.2
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 141.01
Total Assets 4615.84
Total Liabilities 4615.84
Total Equity 1841.86
Share Outstanding 180852000
Price to Book Ratio 0.00
Return on Assets (%) 3.46
Return on Capital (%) 4.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.88
Total Assets 4323.18
Total Liabilities 4323.18
Total Equity 1712.52
Share Outstanding 180852000
Price to Book Ratio 0.00
Return on Assets (%) 10.33
Return on Capital (%) 13.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 260.72
Total Assets 4863.19
Total Liabilities 4863.19
Total Equity 2301.77
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 8.64
Return on Capital (%) 11.66
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.21
Total Assets 3871.20
Total Liabilities 3871.20
Total Equity 1914.55
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 4.52
Return on Capital (%) 5.98
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 28.50
Total Assets 3577.56
Total Liabilities 3577.56
Total Equity 1777.50
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 7.92
Return on Capital (%) 10.27
Particulars MAR 2024 (Values in Cr)
Net Income 727.22
Cash from Operations 1320.89
Cash from Investing -712.51
Cash from Financing -164.20
Net change in Cash 220.52
Free Cash Flow 1596.66
Particulars MAR 2023 (Values in Cr)
Net Income 747.21
Cash from Operations 947.32
Cash from Investing -467.68
Cash from Financing -145.39
Net change in Cash 133.77
Free Cash Flow 1337.92
Particulars MAR 2022 (Values in Cr)
Net Income 972.54
Cash from Operations 1079.38
Cash from Investing -788.79
Cash from Financing -151.85
Net change in Cash -172.43
Free Cash Flow 1482.58
Particulars MAR 2021 (Values in Cr)
Net Income 657.32
Cash from Operations 904.86
Cash from Investing -251.84
Cash from Financing -188.90
Net change in Cash 259.06
Free Cash Flow 1050.53
Particulars MAR 2020 (Values in Cr)
Net Income 105.33
Cash from Operations 592.45
Cash from Investing -163.76
Cash from Financing -300.51
Net change in Cash 36.02
Free Cash Flow 747.10
Particulars MAR 2023 (Values in Cr)
Net Income 212.33
Cash from Operations 589.91
Cash from Investing -270.43
Cash from Financing -54.51
Net change in Cash 180.29
Free Cash Flow 861.57
Particulars MAR 2022 (Values in Cr)
Net Income 616.42
Cash from Operations 598.38
Cash from Investing -188.99
Cash from Financing -342.96
Net change in Cash -309.06
Free Cash Flow 772.45
Particulars MAR 2021 (Values in Cr)
Net Income 557.44
Cash from Operations 888.54
Cash from Investing -831.16
Cash from Financing 30.97
Net change in Cash -29.93
Free Cash Flow 988.63
Particulars MAR 2020 (Values in Cr)
Net Income 224.68
Cash from Operations 415.96
Cash from Investing -164.76
Cash from Financing -45.86
Net change in Cash 170.44
Free Cash Flow 516.70
Particulars MAR 2019 (Values in Cr)
Net Income 369.83
Cash from Operations 496.61
Cash from Investing -275.75
Cash from Financing -53.46
Net change in Cash 41.80
Free Cash Flow 784.47
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 62.47 40.56 3.49 478.73 34.03 / 77.70
BLISS GVS PHARMA LTD 127.90 13.16 1.39 1344.80 77.65 / 148.95
CIPLA LTD 1651.90 30.01 4.99 133401.99 1132.00 / 1682.75
FERMENTA BIOTECH LIMITED 297.15 0.00 3.02 874.54 144.45 / 332.50
GLAXOSMITHKLINE PHARMA LT 2795.20 61.47 26.63 47352.37 1387.90 / 3087.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 62.47 94.65 11.88 478.73 34.03 / 77.70
AMRUTAJAN HEALTH LTD 805.95 54.71 8.07 2330.05 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6703.00 127.92 23.53 16757.50 4050.15 / 7550.00
BLISS GVS PHARMA LTD 127.90 13.77 1.36 1344.80 77.65 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1477.50
  • 26 Days 1395.90
  • 10 Days 1449.90
  • 50 Days 1375.90
  • 12 Days 1441.30
  • 100 Days 1362.90
  • 20 Days 1421.90
  • 200 Days 1358.90
1543.40
PIVOT
First Resistance 1563.20
Second Resistance 1599.80
Third Resistance 1619.60
First Support 1506.80
Second Support 1487.00
Third Support 1450.40
RSI 77.54
MACD 45.36
Commodity Channel Index (CCI) 312.71
ADX 53.04
Williams % R -26.13

Over 1 Month

down

15.21

Over 3 Months

down

12.32

Over 6 Months

down

0.00

Over 1 Year

down

0.00

Over 3 Years

down

0.00

Over 5 Years

down

0.00

Emcure Pharmaceuticals Limited Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

Emcure Pharmaceuticals Limited Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
18.39
Promoter Holdings
78.08
FII
1.75
DII
1.76
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Satish R Mehta Shareholding of Promoter and Promoter Group 7.5396748E7 39.87
Bc Investments Iv Limited Public Shareholding 1.6439459E7 8.69
Everest Trust (Shares held by Sanjay Rajnikant Mehta with Sonali Mehta, as Trustees) Shareholding of Promoter and Promoter Group 1.452E7 7.68
Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as Trustees) Shareholding of Promoter and Promoter Group 1.4508E7 7.67
Samit S Mehta Shareholding of Promoter and Promoter Group 1.3537632E7 7.16
Bhavana Satish Mehta Shareholding of Promoter and Promoter Group 8916888.0 4.72
Namita Vikas Thapar Shareholding of Promoter and Promoter Group 5071200.0 2.68
Pushpa Rajnikant Mehta Shareholding of Promoter and Promoter Group 3886052.0 2.06
Sanjay Rajnikant Mehta Shareholding of Promoter and Promoter Group 3704028.0 1.96
Sunil Rajnikant Mehta Shareholding of Promoter and Promoter Group 2847012.0 1.51
Kamini Sumil Mehta Shareholding of Promoter and Promoter Group 1664960.0 0.88
Niraj Sunil Mehta Shareholding of Promoter and Promoter Group 1100000.0 0.58
Rutav Sunil Mehta Shareholding of Promoter and Promoter Group 988224.0 0.52
Vikas M Thapar Shareholding of Promoter and Promoter Group 645000.0 0.34
Surekha Umakant Shah Shareholding of Promoter and Promoter Group 318216.0 0.17
Suhasinee Saumil Shah Shareholding of Promoter and Promoter Group 129216.0 0.07
Sunita Paresh Shah Shareholding of Promoter and Promoter Group 129216.0 0.07
Girish Harrai Desai Shareholding of Promoter and Promoter Group 115716.0 0.06
Shaila Sharad Gurjar Shareholding of Promoter and Promoter Group 77530.0 0.04
Swati Hetalkumar Shah Shareholding of Promoter and Promoter Group 64716.0 0.03
Ranjankumari Mukeshbhai Desai Shareholding of Promoter and Promoter Group 28928.0 0.02

Emcure Pharmaceuticals Limited

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About Emcure Pharmaceuticals Limited

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Emcure Pharmaceuticals Limited

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Emcure Pharmaceuticals Ltd?

Answer Field

The share price of Emcure Pharmaceuticals Ltd for NSE is ₹ 1461.55 and for BSE is ₹ 1477.

What is the Market Cap of Emcure Pharmaceuticals Ltd?

Answer Field

The market cap of Emcure Pharmaceuticals Ltd for NSE is ₹ 2,64,76.29 Cr. and for BSE is ₹ 2,67,56.17 Cr. as of now.

What is the 52 Week High and Low of Emcure Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Emcure Pharmaceuticals Ltd for NSE is ₹ 1580.00 and ₹ 1225.00 and for BSE is ₹ 1577.50 and ₹ 1226.50.

How to Buy Emcure Pharmaceuticals Ltd share?

Answer Field

You can trade in Emcure Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Emcure Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 0.00%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4800 Cr MTF Book

icon-with-text
loader